Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 37Carcinoma, Hepatocellular 20Neoplasm Metastasis 19Lung Neoplasms 19Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Basal Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Sarcoma 5

Interventions

pazopanib 2Ifosfamide 2Doxorubicin 2tazemetostat 1selinexor 1Radiotherapy 1Radiation 1Proton Therapy 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nerve Sheath Neoplasms × Nivolumab × 90 days × Clear all
NCT04465643 2026-05-29

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
13 enrolled

Nerve Sheath Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡